跟踪非酒精性脂肪性肝病的临床试验-药物分类

贾寒; 饶慧瑛

doi:10.3969/j.issn.1001-5256.2018.12.002

跟踪非酒精性脂肪性肝病的临床试验-药物分类

DOI: 10.3969/j.issn.1001-5256.2018.12.002

贾寒,
饶慧瑛

北京大学人民医院北京大学肝病研究所

详细信息

中图分类号: R575
计量
- 文章访问数: 1632
- HTML全文浏览量: 14
- PDF下载量: 454
- 被引次数: 0
出版历程
- 出版日期: 2018-12-20

Clinical trials tracking nonalcoholic fatty liver disease: Drug classification

摘要

摘要: 目前尚无针对非酒精性脂肪性肝病(NAFLD)公认疗效的药物上市,有许多药物正在进行临床试验。这些药物从不同的作用机制,例如改善糖脂代谢、抗炎、抗纤维化及改善肠道菌群等方面,发挥治疗作用。通过对靶向炎症反应和免疫激活,靶向脂质代谢和胰岛素抵抗,靶向脂毒性、氧化应激和细胞凋亡和坏死,靶向胶原形成和胶原降解,以及改变肠道菌群增殖等几个方面对这些药物研发情况进行了阐述。
- 非酒精性脂肪性肝病 /
- 药物,临床试用 /
- 代谢综合征X /
- 肝硬化
Abstract: At present, there are still no effective drugs launched for the treatment of nonalcoholic fatty liver disease (NAFLD) , and many drugs are being evaluated in clinical trials. These drugs have different mechanisms of action in treatment, such as improvement of glycolipid metabolism, anti-inflammation, anti-fibrosis, and improvement of intestinal microbiota. This article elaborates on the research and development of drugs from the following aspects: inflammatory response and immune activation, lipid metabolism and insulin resistance, lipotoxicity, oxidative stress, cell apoptosis and necrosis, collagen formation and degradation, and proliferation of intestinal microbiota.
- non-alcoholic fatty liver disease /
- drugs, investigational /
- metabolic syndrome X /
- liver cirrhosis

HTML全文

参考文献(32)

[1] LOOMBA R, SANYAL AJ. The global NAFLD epidemic[J]. Nat Rev Gastroenterol Hepatol, 2013, 10 (11) :686-690.

[2] ZHU CY, ZHOU D, FAN JG. Advances in diagnosis and treatment of nonalcoholic fatty liver disease[J]. Chin J Hepatol, 2016, 24 (2) :81-84. (in Chinese) 朱婵艳, 周达, 范建高.非酒精性脂肪性肝病的诊断与治疗进展[J].中华肝脏病杂志, 2016, 24 (2) :81-84.

[3] National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol, 2018, 34 (5) :947-957. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南 (2018年更新版) [J].临床肝胆病杂志, 2018, 34 (5) :947-957.

[4] TILG H, CANI PD, MAYER EA. Gut microbiome and liver diseases[J]. Gut, 2016, 65 (12) :2035-2044.

[5] VILAR-GOMEZ E, MARTINEZ-PEREZ Y, CALZADILLABERTOT L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis[J]. Gastroenterology, 2015, 149 (2) :367-378.

[6] RATZIU V, HARRISON SA, FRANCQUE S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-αand-δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J]. Gastroenterology, 2016, 150 (5) :1147-1159.

[7] BELFORT R, HARRISON SA, BROWN K, et al. A placebo controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis[J]. N Engl J Med, 2006, 355 (22) :2297-2307.

[8] AITHAL GP, THOMAS JA, KAYE PV, et al. Randomized, placebo controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis[J]. Gastroenterology, 2008, 135 (4) :1176-1184.

[9] DEPAOLI AM, HIGGINS LS, HENRY RR, et al. Can a selective PPARγmodulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?[J]. Diabetes Care, 2014, 37 (7) :1918-1923.

[10] JAIN MR, GIRI SR, TRIVEDI C, et al. Saroglitazar, a novel PPARα/γagonist with predominant PPARαactivity, shows lipid lowering and insulin-sensitizing effects in preclinical models[J].Pharmacol Res Perspect, 2015, 3 (3) :e00136.

[11] JANI RH, PAI V, JHA P, et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI) [J]. Diabetes Technol Ther, 2014, 16 (2) :63-71.

[12] MARKHAM A, KEAM SJ. Obeticholic acid:First global approval[J]. Drugs, 2016, 76 (12) :1221-1226.

[13] NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, non-alcoholic steatohepatitis (FLINT) :A multicentre, randomised, placebo-controlled trial[J]. Lancet, 2015, 385 (9972) :956-965.

[14] RATZIU V, de LEDINGHEN V, OBERTI F, et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis[J]. J Hepatol, 2011, 54 (5) :1011-1019.

[15] VATNER DF, WEISMANN D, BEDDOW SA, et al. Thyroid hormone receptor-βagonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways[J]. Am J Physiol Endocrinol Metab, 2013, 305 (1) :e89-e100.

[16] SAFADI R, KONIKOFF FM, MAHAMID M, et al. The fatty acid-bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2014, 12 (12) :2085-2091.

[17] MUSSO G, CASSADER M, GAMBINO R. Cholesterol lowering therapy for the treatment of nonalcoholic fatty liver disease:An update[J].Curr Opin Lipidol, 2011, 22 (6) :489-496.

[18] GILEAD SCIENCES, INC. Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver CongressTM 2017 Gilead[R/OL].[2017-04-21]. https://www. gilead. com/news/press-releases/2017/4/gilead-presents-proofofconcept-data-for-gs0976-in-nonalcoholic-steatohepatitis-nash-at-the-international-livercongress-2017

[19] ARMSTRONG MJ, GAUNT P, AITHAL GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN) :A multicentre, double-blind, randomised, placebocontrolled phase 2 study[J]. Lancet, 2016, 387 (10019) :679-690.

[20] CUI J, PHILO L, NGUYEN P, et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease:A randomized controlled trial[J]. J Hepatol, 2016, 65 (2) :369-376.

[21] JOY TR, MCKENZIE CA, TIRONA RG, et al. Sitagliptin in patients with non-alcoholic steatohepatitis:A randomized, placebocontrolled trial[J]. World J Gastroenterol, 2017, 23 (1) :141-150.

[22] BUGIANESI E, GENTILCORE E, MANINI R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease[J]. Am J Gastroenterol, 2005, 100 (5) :1082-1090.

[23] UYGUN A, KADAYIFCI A, ISIK AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis[J]. Aliment Pharmacol Ther, 2004, 19 (5) :537-544.

[24] SEKO Y, SUMIDA Y, TANAKA S, et al. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus[J]. Hepatol Res, 2017, 47 (10) :1072-1078.

[25] KOMIYA C, TSUCHIYA K, SHIBA K, et al. Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type2 diabetic patients irrespective of body weight reduction[J]. PLo S One, 2016, 11 (3) :e0151511.

[26] TAKASE T, NAKAMURA A, MIYOSHI H, et al. Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin:An association with glucose-lowering effects[J]. Endocr J, 2017, 64 (3) :363-367.

[27] SANYAL AJ, CHALASANI N, KOWDLEY KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med, 2010, 362 (18) :1675-1685.

[28] POCKROS PJ, SCHIFF ER, SHIFFMAN ML, et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C[J]. Hepatology, 2007, 46 (2) :324-329.

[29] BARREYRO FJ, HOLOD S, FINOCCHIETTO PV, et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis[J].Liver Int, 2015, 35 (3) :953-966.

[30] ZEIN CO, YERIAN LM, GOGATE P, et al. Pentoxifylline improves nonalcoholic steatohepatitis:A randomized placebo-controlled trial[J]. Hepatology, 2011, 54 (5) :1610-1619.

[31] SHIRAKAMI Y, SHIMIZU M, KUBOTA M, et al. Pentoxifylline prevents nonalcoholic steatohepatitis-related liver pre-neoplasms by inhibiting hepatic inflammation and lipogenesis[J]. Eur J Cancer Prev, 2016, 25 (3) :206-215.

[32] CAO Y, SHEN F, XU LM, et al. Assoclation of gut microbiota with endotoxemia and nonalcoholic fatty liver disease[J]. J Pract Hepatol, 2012, 15 (2) :163-165. (in Chinese) 曹毅, 沈峰, 徐雷鸣, 等.肠道菌群和内毒素血症与非酒精性脂肪性肝病[J].实用肝脏病杂志, 2012, 15 (2) :163-165.

施引文献

资源附件(0)

访问统计